The company’s performance reflects a shift toward higher product-driven income, which reached $239 million for the quarter. Sephience, the company’s sepiapterin-based therapy, contributed $151 million alone, supporting a patient base that now spans 1,647 individuals worldwide. This growth helped offset the ongoing generic erosion impacting Emflaza and shifting demand for Translarna. CEO Matthew B. Klein noted that beyond commercial gains, the firm successfully advanced its research pipeline, including the identification of PTC303 for Huntington’s disease and myotonic dystrophy.
Financially, the company maintains a robust liquidity position with $2.2 billion in cash and marketable securities as of June 30. The quarter also saw a $50 million milestone payment from Novartis, triggered by the initiation of the Phase 3 INVEST-HD study. Looking ahead, PTC plans to engage with the FDA later this year regarding 24-month data from the PIVOT-HD study, while preparing for a third-quarter launch of the PROVE-FA study to support an NDA resubmission for Friedreich’s ataxia treatment.
Comments (0)
No comments yet. Be the first!